We are enrolling an open-label dose-escalation study on the effectiveness of ARX-788 in patients with advanced cancers with HER2 expression. ARX788 is a conjugate of a HER2 targeted antibody with two cytotoxic payloads site-specifically conjugated. It is designed to form a highly stable covalent bond and kill tuor cells only upon entry into the cell – potentially limiting effects on health tissue.
Phase 1a of this study is designed to determine the recommended dose for Phase 2 in subjects with advanced cancer whose HER2 test results are positive. Phase 1b is designed to assess anticancer activity and safety in 2 advanced breast cancer expansion cohorts.
We are currently recruiting patients in California, Missouri, Ohio, and Texas in the United States, as well as New South Wales, Queensland and Victoria in Australia.